Search Results - "Collins, G.P."

A phase I trial to assess the safety, PK and PD of CXD101 in advanced cancer expressing the biomarker HR23B by Eyre, T.A., Collins, G.P., Gupta, A., Sheikh, S., Woodcock, V., Whittaker, J., Wang, L.M., Soilleux, E., Tysoe, F., Cousins, R., Thangue, N.L.a., Kerr, D., Middleton, M.R.

Get full text

PF721 MINIMAL CLINICALLY IMPORTANT DIFFERENCE AND RESPONSIVENESS FOR HM‐PRO IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES by Goswami, P., Ionova, T., Oliva, E.N., Else, R., Kell, J., Fielding, A.K., Jennings, D.M., Karakantza, M., Al‐Ismail, S., Collins, G.P., McConnell, S., Langton, C., Salek, S.

“…Background: Minimal clinically important difference (MCID) of a patient‐reported outcome (PRO) measure is the smallest change in the scores that is meaningful…”
Get full text

PHASE 1/2A CLINICAL TRIALS OF BI‐1206, A MONOCLONAL ANTIBODY TO FCΓRIIB, ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH B‐CELL MALIGNANCIES by Karlsson, I., Traub, S., Järås, K., Edwards, D., Gramming, E., Lindell Andersson, M., To, Y., Mårtensson, L., Teige, I., Acton, G., Dyer, M.J., Radford, J., Collins, G.P., Jerkeman, M., Frendéus, B., McAllister, A., Davies, A.

Get full text

Safety and efficacy of single‐agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open‐label, phase 2 study by Collins, G.P., Noy, A., Vos, S., Thieblemont, C., Martin, P., Flowers, C., Morschhauser, F., Ma, S., Coleman, M., Peles, S., Smith, S., Barrientos, J., Smith, A., Munneke, B., Dimery, I., Beaupre, D., Chen, R.

Get full text

RESULTS OF a MULTICENTRE UK‐WIDE STUDY EVALUATING THE EFFICACY OF BRENTUXIMAB VEDOTIN IN RELAPSED, REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN THE PRE‐TRANSPLANT NAÏVE SETTING by Eyre, T.A., Phillips, E.H., Linton, K.M., Kassam, S., Gibb, A., Allibone, S., Peggs, K., Burton, C., Stewart, G., Ledieu, R., Booth, C., Osborne, W., Miall, F., Eyre, D.W., Ardeshna, K., Collins, G.P.

Get full text

BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL) by Chen, R., Gibb, A.L., Collins, G.P., Popat, R., El‐Sharkawi, D., Burton, C., Lewis, D., Miall, F.M., Forgie, A., Compagnoni, A., Andreola, G., Brar, S., Thall, A., Woolfson, A., Radford, J.

Get full text

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN by Hiddemann, W., Barbui, A.M., Canales Albendea, M.A., Cannell, P.K., Collins, G.P., Dürig, J., Forstpointner, R., Herold, M., Hertzberg, M., Klanova, M., Radford, J.A., Tobinai, K., Burciu, A., Fingerle‐Rowson, G.R., Nielsen, T., Wolbers, M., Marcus, R.

Get full text

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL by Fanale, M., Engert, A., Younes, A., Armand, P., Ansell, S., Zinzani, P.L., Timmerman, J.M., Collins, G.P., Ramchandren, R., Cohen, J.B., De Boer, J.P., Kuruvilla, J., Savage, K.J., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B., Santoro, A.

Get full text

THE ROLE OF 18F FDG‐PET/CT IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NCRI MULTICENTRE PHASE II RANDOMISED CHEMO‐T TRIAL PET/CT SUBSTUDY by Gleeson, M., Peckitt, C., Cunningham, D., To, Y.M., Edwards, L., Chau, I., Johnson, P., Ardeshna, K.M., Wotherspoon, A., Attygalle, A., Begum, R., Zerizer, I., Hawkes, E.A., Macheta, M.P., Collins, G.P., Radford, J.A., Forbes, A., Hart, A., Montoto, S., McKay, P., Benstead, K., Morley, N., Kalakonda, N., Hasan, Y., Turner, D., Chua, S.

Get full text

CHOP VERSUS GEM‐P IN THE FIRST‐LINE TREATMENT OF T‐CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO‐T TRIAL by Gleeson, M., Peckitt, C., To, Y.M., Edwards, L., Chau, I., Johnson, P., Ardeshna, K.M., Wotherspoon, A., Attygalle, A., Begum, R., Chua, S., Zerizer, I., Hawkes, E.A., Macheta, M.P., Collins, G.P., Radford, J.A., Forbes, A., Hart, A., Montoto, S., McKay, P., Benstead, K., Morley, N., Kalakonda, N., Hasan, Y., Turner, D., Cunningham, D.

Get full text

Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma by LITTLEWOOD, T. J, COLLINS, G. P

“…High-dose chemotherapy is an established treatment for patients with myeloma. In randomized trials it has been shown to prolong disease-free survival by around…”
Get full text

Current treatment and future prospects for peripheral T-cell lymphoma by Eyre, T A, Collins, G P

“…The management of peripheral T-cell lymphoma (PTCL) remains a big challenge. PTCL exists as a collection of subentities, which are all rare. Each subtype…”
Get full text

Comment on the use of doubled surfaces by COLLINS, G. P

Get full text

A comparative study in obstetrics in an urban area on 10,000 African and 2,000 European deliveries by COLLINS, J, FISHER, A C, NIXON, G P

Get more information

Methotrexate-induced sudden fatal pulmonary reaction by Lascari, A D, Strano, A J, Johnson, W W, Collins, J G

“…A teenage girl in bone marrow remission with acute lymphocytic leukemia died suddenly from pulmonary edema. She had taken her first oral dose of methotrexate…”
Get more information